MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Memantine Hydrochloride And Donepezil Hydrochloride, and when can generic versions of Memantine Hydrochloride And Donepezil Hydrochloride launch?
Memantine Hydrochloride And Donepezil Hydrochloride is a drug marketed by Amneal Pharms and Ani Pharms and is included in two NDAs.
The generic ingredient in MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE is donepezil hydrochloride; memantine hydrochloride. There are thirty-two drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the donepezil hydrochloride; memantine hydrochloride profile page.
Summary for MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 2 |
NDAs: | 2 |
Finished Product Suppliers / Packagers: | 1 |
Clinical Trials: | 25 |
Formulation / Manufacturing: | see details |
DailyMed Link: | MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Peking Union Medical College Hospital | Phase 2 |
Tongji University | Phase 2 |
Zealand University Hospital | Phase 4 |
See all MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE clinical trials
Pharmacology for MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE
Drug Class | Cholinesterase Inhibitor N-methyl-D-aspartate Receptor Antagonist |
Mechanism of Action | Cholinesterase Inhibitors NMDA Receptor Antagonists |
Anatomical Therapeutic Chemical (ATC) Classes for MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE
US Patents and Regulatory Information for MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE
EU/EMA Drug Approvals for MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
H. Lundbeck A/S | Acrescent | memantine hydrochloride, donepezil hydrochloride | EMEA/H/C/002424 Treatment of Alzheimers disease |
Refused | no | no | no | 2013-02-20 | |
Merz Pharmaceuticals GmbH | Balaxur | memantine hydrochloride, donepezil hydrochloride | EMEA/H/C/002708 |
Refused | no | no | no | 2013-02-20 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |